ACSS3

Across TCGA pan-cancer cohorts, ACSS3 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of ACSS3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ACSS3 RNA is repressed in tumor relative to normal tissue. In most cancer types ACSS3 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and UCEC are the cancer types where ACSS3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACSS3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−2.031	<.001	11	view →
LUSC	All	III,IV	−1.920	<.001	9	view →
UCEC	All	III,IV	−2.143	<.001	8	view →
BLCA	Male	All	−0.995	<.001	6	view →
BRCA	Female	All	−0.964	<.001	6	view →
HNSC	Male	All	−0.649	<.001	6	view →
THCA	Male	All	−0.604	.001	6	view →
KIRC	All	All	−0.414	.002	6	view →
KICH	Female	All	+1.612	<.001	5	view →
COAD	All	II,III,IV	−0.230	.006	5	view →
CHOL	Male	All	−2.261	<.001	4	view →
KIRP	All	All	−0.787	.006	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

ACSS3–LUAD

Open the LUAD breakdown →